Neumora Therapeutics said yesterday it will stop development of its depression drug candidate, after the treatment failed to show statistically significant improvements in two Phase 3 studies.
It will also lay off about 35% of its workforce. Learn more. trib.al/yCvEfeZ
Weight loss drugs will be available through Medicare starting next month, thanks to a program that is supposed to be temporary but may be difficult to end trib.al/aKyFmOu
In 1999, 51% of American adults took supplements, compared to 60% in 2023.
Vitamin use increased, but multivitamin-multimineral use actually decreased, which the researchers propose is connected to a growing preference for personalized medicine. trib.al/o6yXKq9
As the saying goes, one man’s trash is another man’s treasure. Or as Verge Labs might put it, one company’s failed clinical trial … is that same company’s new AI… trib.al/hafEwR5
As the Human Cell Atlas project marks its 10th anniversary, a leader's ties to a major single-cell RNA sequencing company raise conflict-of-interest questions. trib.al/ubbHI0I
The director-general of the World Health Organization is “really worried” about the Ebola outbreak in the Democratic Republic of the Congo and Uganda, already the third largest on record. trib.al/coSJVec
A new analysis found that results for less than half of the clinical studies registered in a key European database were reported within the required time frame. trib.al/Lb3o4qG
How is leadership turmoil reshaping the FDA? Why did the NIH foundation crack? What's really happening with AI and health care costs? STAT subscribers get answers to the questions that matter — plus 25% off through June 17. trib.al/HyrNisg
Eli Lilly unveiled the first clinical data behind its up-to-$2.3 billion acquisition of Ajax Therapeutics — and revealed a serious challenger to market drugs for myelofibrosis. Read more. trib.al/wrSvlUP